Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the ona domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/risezcom/public_html/cord-blood.org.uk/wp-includes/functions.php on line 6170
Cancer Treatment - Cord Blood CAR NK Cells Show Promise - Cord Blood

Cord Blood

and Stem Cell Banking

Cancer Treatment – Cord Blood CAR NK Cells Show Promise

Abstract image of a human gene

Researchers from The University of Texas MD Anderson Cancer Center have made a significant breakthrough, with their latest study showcasing the potential of a novel therapy involving cord blood-derived cells.

To grasp the significance of this advancement, it’s essential to understand the key players: CAR NK cells and their targets, B-cell malignancies.

What are CAR NK Cells?

CAR NK cells, or Chimeric Antigen Receptor Natural Killer cells, are a type of immune cell modified in the lab to recognise and attack cancer cells. Unlike traditional therapies, these cells are engineered to specifically target cancerous cells, reducing damage to healthy cells.

Targeting B-Cell Malignancies

B-cell malignancies are types of cancer that affect B cells, an essential component of the immune system. These include conditions like non-Hodgkin lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma.

Promising Results and Safety

The study, published in Nature Medicine, involved 37 patients with relapsed or refractory B-cell malignancies. They underwent treatment with CAR NK cells derived from cord blood, a new approach in cancer therapy.

The results were promising: an overall response rate of 48.6% at 100 days post-treatment. What’s more, one-year progression-free survival (PFS) and overall survival (OS) rates were 32% and 68%, respectively. These numbers are particularly encouraging, considering the participants had forms of cancer resistant to other treatments.

One of the most remarkable aspects of this study is its safety profile. There were no cases of severe cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host disease – common complications in similar therapies.

The Importance of Donor Selection in CAR NK Cell Manufacturing

A key discovery of the trial was how the choice of cord blood donors impacts the treatment’s success. Units of cord blood cryopreserved within 24 hours of collection and with a low nucleated red blood cell content led to significantly better outcomes.

When these criteria were met, the one-year PFS rate jumped to 69%, and the OS rate soared to 94%. This is a stark contrast to rates from less ideal units, highlighting the critical role of donor selection in this therapy’s efficacy.

Durable Responses Across Different Cancer Types

The study also observed promising response rates across various B-cell malignancies, with complete responses seen in a significant portion of patients one year after treatment. The effectiveness of this therapy across multiple cancer types indicates its potential as a versatile treatment option.

The Future of CAR NK Cell Therapy

This research not only paves the way for more effective treatments for B-cell malignancies but also opens doors to applying this method to other cancers, including solid tumors.

MD Anderson is already applying these findings in ongoing and future trials, targeting other antigens and malignancies. The goal is to broaden the scope of this therapy, offering hope to more patients.

One of the most exciting prospects of this therapy is its potential for being manufactured in advance and stored for immediate use. This could greatly increase patient access to these treatments, reduce waiting times, and potentially lower costs.